On 1st April, 20X1, Johansen Ltd. acquired a new subsidiary, Bosman Ltd., purchasing all 150 million shares of Bosman Ltd. The terms of the sale…
CA Final · Financial Reporting · MTP · November 2026
On 1st April, 20X1, Johansen Ltd. acquired a new subsidiary, Bosman Ltd., purchasing all 150 million shares of Bosman Ltd. The terms of the sale agreement included the exchange of four shares in Johansen Ltd. for every three shares acquired in Bosman Ltd. On 1st April, 20X1, the market value of a share in Johansen Ltd. was ₹ 10 and the market value of a share in Bosman Ltd. ₹ 12. The terms of the share purchase included the issue of one additional share in Johansen Ltd. for every five acquired in Bosman Ltd., if the profits of Bosman Ltd. for the two years ending 31st March, 20X3 exceeded a target figure. Current estimates are that it is 80% probable that the management of Bosman Ltd. will achieve this target. Legal and professional fees associated with the acquisition of Bosman Ltd. shares were ₹ 12,00,000, including ₹ 2,00,000 relating to the cost of issuing shares. The senior management of Johansen Ltd. estimates that the cost of their time that can be fairly allocated to the acquisition is ₹ 2,00,000. This figure of ₹ 2,00,000 is not included in the legal and professional fees of ₹ 12,00,000 mentioned above. The individual Balance Sheet of Bosman Ltd. at 1st April, 20X1 comprised net assets that had a fair value at that date of ₹ 1,200 million. Additionally, Johansen Ltd. considered Bosman Ltd. possessed certain intangible assets that were not recognized in its individual Balance Sheet: Customer relationships – reliable estimate of value ₹ 100 million. This value has been derived from the sale of customer databases in the past. An in-process research and development project that had not been recognised by Bosman Ltd. since the necessary conditions laid down in Indian Accounting Standards for capitalisation were only just satisfied at 31st March, 20X2. However, the fair value of the whole project (including the research phase) is estimated at ₹ 50 million. Employee expertise – estimated value of Director employees of Bosman Ltd. is ₹ 80 million. The market value of a share in Johansen Ltd. on 31st March, 20X2 was ₹ 11. Required Compute the goodwill on consolidation of Bosman Ltd. that will appear in the consolidated Balance Sheet of Johansen Ltd. at 31st March, 20X2 with necessary explanation of adjustments therein. Also state the treatment of contingent consideration as on 31st March, 20X2.
Suggested Answer and Working Notes:
Calculation of purchase consideration: Particulars ₹ in million Market value of shares issued (150 million x 4/3 x ₹ 10) 2,000 Initial estimate of market value of shares to be issued (150 million x 1/5 x 10) 300 Total consideration 2,300 Contingent consideration is recognized in full if payment is probable.As per para 53 of Ind AS 103, acquisition-related costs are costs the acquirer incurs to effect a business combination. Those costs include finder's fees; advisory, legal, accounting, valuation and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and costs of registering and issuing debt and equity securities. The acquirer shall account for acquisition-related costs as expenses in the periods in which the costs are incurred and the services are received, with one exception. The costs to issue debt or equity securities shall be recognised in accordance with Ind AS 32 and Ind AS 109.Statement of fair value of identifiable net assets at the date of acquisition Particulars ₹ in million As per Bosman Ltd.'s Balance Sheet 1,200 Fair value of customer relationships 100 Fair value of research and development project 50 Total net assets acquired 1,350 As per Ind AS 38 ‘Intangible assets', intangible assets can be recognized separately from goodwill provided they are identifiable, are under the control of the acquiring entity, and their fair value can be measured reliably.Customer relationships that are similar in nature to those previously traded, pass these tests but employee expertise fail the 'control' test. Both the research and development phases of in process project can be capitalised provided their fair value can be measured reliably.Statement of computation of goodwill Particulars ₹ in million Fair value of consideration given 2,300 Fair value of net assets acquired (1,350) Goodwill on acquisition 950 Paragraph 58 of Ind AS 103 provides guidance on the subsequent accounting for contingent consideration. In general, an equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Ind AS 32 describes an equity instrument as one that meets both of the following conditions: There is no contractual obligation to deliver cash or another financial asset to another party, or to exchange financial assets or financial liabilities with another party under potentially unfavourable conditions (for the issuer of the instrument). If the instrument will or may be settled in the issuer's own equity instruments, then it is: a non-derivative that comprises an obligation for the issuer to deliver a fixed number of its own equity instruments; or a derivative that will be settled only by the issuer exchanging a fixed amount of cash or other financial assets for a fixed number of its own equity instruments. In the given case, given that the acquirer has an obligation to issue fixed number of shares on fulfillment of the contingency, the contingent consideration will be classified as equity as per the requirements of Ind AS 32.As per paragraph 58 of Ind AS 103, contingent consideration classified as equity should not be re-measured and its subsequent settlement should be accounted for within equity.
Topics: Ind AS 103
Related Questions in this Topic
- Makers Ltd. acquired 65% of shares on 1 June, 20X3 in D Limited which is engaged in production of components of machiner...
- A Ltd. is preparing its financial statements for the year ended 31 March 20X5. During the year, the following transactio...
- Panama Pharma Ltd. is a leading company engaged in the manufacturing of generic medicines. The company decided to acquir...
- ABC Ltd. is a globally diversified business conglomerate with operations spanning across various business sectors worldw...
- Zest Ltd.is engaged in the manufacturing of Automobiles with its registered office in Pune and is listed on BSE Limited....